ライフサイエンスコーパス: disease score

1 d-Turcotte-Pugh or Model for End-Stage Liver Disease scores).

2 of transplant, and model for end-stage liver disease score.

3 g age, gender, and Model for End-Stage Liver Disease score.

4 o normal or gld recipients gave a diminished disease score.

5 ents with relapsing-remitting MS with a high disease score.

6 y associated with the total MRI small vessel disease score.

7 s who had the same Model for End-Stage Liver Disease score.

8 ory cytokines, and model for end-stage-liver disease scores.

9 malized ratio, and Model for End-Stage Liver Disease scores.

10 ogenic immunization reproducibly ameliorated disease scores.

11 ration of clinical signs, and increased peak disease scores.

12 ents of mutant bone marrow, developed normal disease scores.

13 three expression modules correlated with GLS disease scores.

14 oth Child-Pugh and Model for End-Stage Liver Disease scores.

15 l disease stage and model of end-stage liver disease scoring.

16 tium to Establish a Registry for Alzheimer's Disease score, 1.2 [0.5] vs 1.4 [0.8], respectively; P =

17 ; 35% female; mean Model for End-stage Liver Disease score, 10.8; range, 6-40) underwent MRI.

18 8.3 (+/-1.3), and Model for End-Stage Liver Disease score 11.7 (+/-3.9).

19 7 +/- 3; and mean model for end-stage liver disease score, 13 +/- 6) completed the program.

20 tage Liver Disease/Pediatric End-Stage Liver Disease score (19 vs 11, respectively; P = .48), and don

21 e analyzed (median Model for End-Stage Liver Disease score 20).

22 a higher mean (SD) model for end-stage liver disease score (24 [11] vs. 22 [10], P</=0.05).

23 ing DC had greater Model for End-stage Liver Disease scores (33 vs 27; P < .001); more frequent pretr

24 in group A and had a higher mean concomitant disease score, a higher proportion of men and a greater

25 neurologic deficits as indicated by clinical disease score, activity monitoring, and footprint analys

26 lementation of the model for end-stage liver disease score and a concomitant increase on the rate of

27 tion was evidenced primarily by increases in disease score and degree of inflammation in the CNS.

28 Recipient Model for End-stage Liver Disease score and graft size were not significant predic

29 T to LT, and lower model for end-stage liver disease score and maximum tumor diameter (C-statistic 0.

30 Disease score and paw thickness were measured daily.

31 tium to Establish a Registry for Alzheimer's Disease scores and Braak and Braak stage), and hippocamp

32 er two strains, based on significantly lower disease scores and observably smaller and fewer lesions

33 ciated with higher model for end-stage liver disease scores and receiving a LT from a living donor.

34 luding with Porphyromonas that correlated to disease scores and salivary levels of interleukin (IL)-1

35 istologic sections were used to evaluate EAU disease scores and to assess outer blood retina barrier

36 hinge on regional model for end-stage liver disease scores and waiting time for transplant.

37 tis C virus (HCV), model for end-stage liver disease score, and acute rejection; and donor age and ra

38 lysis requirement, model for end-stage liver disease score, and alcoholic liver disease.

39 x, race/ethnicity, Model for End-Stage Liver Disease score, and liver transplantation (adjusted hazar

40 h of stay, greater Model for End-stage Liver Disease score, and longer warm and cold ischemia times (

41 younger age, lower Model for End-stage Liver Disease score, and shorter time from listing to first do

42 old ischemia time, model for end-stage liver disease score, and steatosis.

43 admissions during the previous year, chronic disease score, and use of non-statin lipid-lowering drug

44 age, coinfection, Model for End-Stage Liver Disease scores, and other potential confounders in a pro

45 ase-expressing virus), significantly reduced disease scores, and resulted in greater survival (P < 0.

46 icant correlations between interstitial lung disease score at CT and age or percentage predicted FVC,

47 3 cm (P=0.02) and model for end-stage liver disease score at listing more than 11 (P=0.04) were inde

48 , body weight, and pediatric end-stage liver disease score at the time of transplant were 13 months,

49 cantly higher mean Model for End-Stage Liver Disease score at time of waitlist registration than othe

50 Mean Model for End-Stage Liver Disease score at transplant was significantly different

51 rk so that patient model for end-stage liver disease scores at transplant is more uniform across regi

52 We constructed a 10-point Binswanger disease score (BDS) with subjective and objective diseas

53 impairment and high model of end-stage liver disease scores before liver transplantation (LT) are inc

54 , the dichotomized model for end-stage liver disease score below and above the median, and the presen

55 ammonia levels or model for end-stage-liver disease scores, but patients in the rifaximin group had

56 on Comorbidity Index (c = 0.653) and Chronic Disease Score (c = 0.608) were similar discriminators of

57 nd mathematical models of prognosis in liver disease scores calculated at day 0, day 3, and day 7.

58 The disease score can be used to establish a criterion and t

59 45, c = 0.745) than medication-based Chronic Disease Score (CDS)-1 and CDS-2 (c = 0.738, c = 0.718).

60 g for age, gender, Model for End-Stage Liver Disease score, Child-Pugh score, serum sodium, previous

61 t groups showed a significant improvement in disease score compared to the control group.

62 refore, the effect of the routine use of the disease score could result in fewer patients with severe

63 osts, and baseline Model for End-Stage Liver Disease score (DCC analysis only).

64 Pediatric End-Stage Liver Disease scores decreased from 16 +/- 4.6 to -1.2 +/- 4.6

65 ntation at a lower model for end-stage liver disease score, decreased death on waitlist, and excellen

66 e immunization in such mice produced similar disease scores, demonstrating that Fas/FasL interactions

67 months; Child and Model for End-Stage Liver Disease scores did not change.

68 The effects of disease distribution (disease score [DS]) and complexity of surgery (complexit

69 onist treatment also resulted in exacerbated disease scores, elevated proinflammatory mediators, and

70 tium to Establish a Registry for Alzheimer's Disease score for neuritic plaques, p = 6.8 x 10-6) and

71 ys (OR 10.23), and Model for End-Stage Liver Disease score greater than 21 (OR 2.5) were significant.

72 ter than 55 years, Model for End-Stage Liver Disease score greater than 27, history of prior OLT grea

73 on of CRE post-LT, Model for End-Stage Liver Disease score greater than 32, combined transplantation,

74 coholic hepatitis (Model for End-Stage Liver Disease score > or = 15) were enrolled and randomized to

75 s mice showing the severe disease phenotype (disease score > or = 3)and 68 backcross mice of the resi

76 years; 48.0% had a Model for End-Stage Liver Disease score >/=20.

77 Model for End-Stage Liver Disease score >/=25 was associated with a lower 12-month

78 gen >27] + 0.4574 [Model for End-Stage Liver Disease score >21] + 1.1625 [intensive care unit days >3

79 creatinine in the model for end-stage liver disease score has significantly increased the incidence

80 in recipients with model of end-stage liver disease score higher than 27 (13.2% vs. 23.0%, P < 0.001

81 nd inflammation were quantified by gross gut disease scoring, histologic scoring, type I collagen, an

82 is also identified Model for End-Stage Liver Disease score, hypovolemic shock, and bacterial infectio

83 oid insufficiency, Model for End-Stage Liver Disease score, hypovolemic shock, hepatocellular carcino

84 -Turcotte-Pugh and model for end-stage liver disease scores improved significantly from baseline to 6

85 concept validity of a total MRI small vessel disease score in CAA.

86 r of relapses and diminished mean cumulative disease score in chronic relapsing animals.

87 ticeable for lower model for end-stage liver disease scores in LD recipients (P<0.001) and younger do

88 dy to CLEC12A that significantly ameliorated disease scores in MOG35-55-induced progressive, as well

89 The data indicate that high disease scores in response to IRBP and p161-180 were fou

90 e Charlson Comorbidity Index and the Chronic Disease Score, in assessing the comorbidity-attributable

91 -Turcotte-Pugh and model for end-stage liver disease scores, in patients with cirrhosis.

92 (age of recipient, model for end-stage liver disease score, indication for LT, platelet count, and re

93 The group with severe disease scored lower than the norm across all domains (E

94 raft survival than Model for End-Stage Liver Disease score <15 (P=0.02).

95 to those with lower Model of End-Stage Liver Disease scores (</=15).

96 recipients with low model of end-stage liver disease scores (<27), without hepatitis C, not hospitali

97 8%), and had lower model for end-stage liver disease scores (median 9 versus 10) (all P < 0.05).

98 ege Criteria (KCC), Model of End Stage Liver Disease score (MELD), and serum sodium based modificatio

99 D angiographic score of 0), mild-to-moderate disease (score of 1 to 3), and severe disease (score of

100 derate disease (score of 1 to 3), and severe disease (score of 4 to 6) had median F11R plasma levels

101 ated with having a model for end-stage liver disease score of 20 or greater (hazards ratio, 2.90; 95%

102 11.7 years with a mean Model End-Stage Liver Disease score of 22.6 +/- 9.8.

103 p, or as a single dose upon acquisition of a disease score of 3 (late therapy group.

104 ugh a good correlation was found between the disease score of individual mice and some readout parame

105 dates with a final Model for End-stage Liver Disease score of less than 15.

106 acute rise in the Model for End-Stage Liver Disease score of more than 5 within 4 weeks before trans

107 iver when they had Model for End-stage Liver Disease scores of 15 or greater (P = .005).

108 ovided by studies of C3 knockout mice, where disease scores of gC-null virus were significantly highe

109 obal rating of the change in the severity of disease, scored on a scale of -3.0 to 3.0 at one year, w

110 sis and with worse Model for End-Stage Liver Disease score or diabetes, those taking prophylactic ant

111 post-ECP were compared with changes in skin disease scores or global organ involvement, or the abili

112 asures, paw swelling (P < 0.01) and clinical disease score (P < 0.0001).

113 (P < 0.001), worse Model for End-Stage Liver Disease score (P < 0.001), more portosystemic collateral

114 ion (P < 0.01), and nonalcoholic fatty liver disease score (P < 0.03).

115 gistic regression model showed that only the disease score (P <0.0005) was significantly associated w

116 arance (cCrCl) and Pediatric End-Stage Liver Disease score (PELD).

117 : Child-Pugh class, model of end-stage liver disease score, pre- and post-DIPS PSGs, pre-DIPS liver f

118 tium to Establish a Registry for Alzheimer's Disease scores, presence of alpha-synuclein and TAR DNA-

119 y lower laboratory model for end-stage liver disease scores, pretransplant alpha fetoprotein, and cum

120 The disease score provides an objective means to quickly det

121 An increase in the disease score provides evidence that a new treatment pla

122 ificantly with the Model for End-Stage Liver Disease score (r = -0.39, P < 0.05), fasting venous ammo

123 lure as assessed by model for endstage liver disease score (r = 0.41, P = 0.006) and Maddrey's discri

124 ces (a measure of day of onset and sustained disease scores) ranging from 367 to 663 with central ner

125 to a prespecified ordinal total small vessel disease score, ranging from 0 to 6 points.

126 Seventy-six subjects with a Rasmussen Disease Score (RDS) of 6 or higher were randomized doubl

127 PN-dependent, the Pediatric End-Stage Liver Disease score remained normal throughout the follow-up p

128 ice on average had lower cumulative clinical disease scores, shorter duration of clinical signs, and

129 in recipient age, model for end-stage liver disease score, steatosis, and ischemia times for the pea

130 counted for by the model for end-stage liver disease scoring system and may benefit from the increase

131 A disease scoring system has been developed using 10 tests

132 he combination of risk score and periodontal disease score than by either score alone.

133 milar earlier onset and more severe clinical disease score than WT mice engrafted with WT bone marrow

134 opensity score and Model for End-Stage Liver Disease score, the NSBB adjusted odds ratio for 6-week m

135 As judged by disease scores, three of the strains were susceptible, o

136 P = 0.03) and United Kingdom endstage liver disease score (UKELD) score (59 versus 57, P = 0.01) sig

137 the United Kingdom Model of End Stage Liver Disease score (UKELD) were calculated and area under the

138 ve prostate cancer phenotype with linkage-of-disease scores up to 2.16 and nonparametric linkage scor

139 erimental autoimmune encephalomyelitis (EAE) disease scores via the ligand-activated transcription fa

140 dly reduced virulence in vivo as measured by disease scores, virus titers, and mortality.

141 The P value for the disease score was <0.0005, and the P value for the risk

142 edian preoperative model for end-stage liver disease score was 12.

143 ears, and the mean model for end-stage liver disease score was 12.2 +/- 4.6.

144 The mean Model for End-Stage Liver Disease score was 14.5 +/- 4.

145 Model for End-Stage Liver Disease score was 15 (IQR, 11-21); cold ischemia time, 8

146 The average Model for End-Stage Liver Disease score was 33.

147 Higher model for end-stage liver disease score was associated with increased graft failur

148 The mean end change in disease score was compared between groups.

149 The United Kingdom End-Stage Liver Disease score was not associated with overall posttransp

150 The baseline Model for End-Stage Liver Disease score was not predictive of long-term outcome, w

151 5%-21.3%); the mean nonalcoholic fatty liver disease score was reduced from 5 (IQR, 4-5) to 1 (IQR, 1

152 Agreement between CT and MR imaging disease scores was assessed by using the kappa test.

153 and lower baseline Model for End-Stage Liver Disease score were associated with better survival.

154 ille model and the Model for End-Stage Liver Disease score were independently associated with 6-month

155 Mean model for end-stage liver disease scores were 21.64 in the HCV group and 21.30 in

156 Disease scores were analyzed in reconstituted mice and c

157 ate Child-Pugh and Model for End-Stage Liver Disease scores were recorded.

158 seline (P = .001); Model for End Stage Liver Disease scores were reduced by 40.4% and 33%, respective

159 During the development of colitis, clinical disease scores were reduced by 50% (P < 0.001), and hist

160 Average clinical disease scores were significantly lower in peptide treat

161 were depleted of Vgamma4(+) cells, clinical disease scores were significantly reduced and the incide

162 tween social disadvantage and CMR or chronic disease scores while adjusting for childhood covariates

163 isk Index with the model for end-stage liver disease score yields an AUC-ROC of 0.764 (95% CI, 0.756-